HIV-MAG DNA vaccine + interleukin-12 plasmid DNA + Ad35

The HIV-MAG DNA vaccine regimen is an investigational preventive HIV vaccine strategy developed through a collaboration between Ichor Medical Systems, the International AIDS Vaccine Initiative (IAVI), and Profectus Biosciences. The regimen utilizes a prime-boost approach centered on a multi-antigenic plasmid DNA (pDNA) vaccine (HIV-MAG) that encodes several HIV-1 proteins, including Gag, Pol, Nef, Tat, Vif, and Envelope. To enhance the resulting immune response, the DNA vaccine is co-administered with GENEVAX IL-12, a plasmid DNA encoding interleukin-12 that acts as a molecular adjuvant. Delivery of these DNA components is achieved via intramuscular injection followed by electroporation using Ichor Medical Systems' proprietary TriGrid Delivery System (TDS-IM), which significantly increases cellular uptake. The protocol may also include a subsequent boost with recombinant adenovirus serotype 35 (Ad35) viral vectors (Ad35-GRIN/Env) to further stimulate robust CD4+ and CD8+ T-cell mediated immunity against HIV antigens.

Other names

HIV-MAG DNA vaccine + interleukin-12 plasmid DNA + Ad35-Ichor Systems-HIV MAG-DNA vaccine (HIV-MAG)-IL-12 plasmid adjuvant (optional)-Ad35 viral-vector boost (optional)-Electroporation (TriGrid) for DNA vaccine; Ad35 boost route not specified-HIVHIV-MAG DNA vaccine regimenIAVI B001IAVI B002